Mechanism
JAK1 / JAK3 (with lesser JAK2 activity); metformin arm targets AMPK/hepatic gluconeogenesis
Assets acting on this target.
- Class
- Combination regimen: JAK inhibitor (tofacitinib/CP-690,550) plus metformin (biguanide, not itself an RA drug)
- Pathway
- Tofacitinib blocks JAK-STAT cytokine signaling; metformin studied as an adjunct via AMPK activation
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.